Accenture PLC (NYSE:ACN) shares traded slightly lower in Wednesday's premarket session after the company agreed to acquire two Engineering Group businesses, Alfahealth and Industries eXcellence Group.
Accenture Expands Siemens Capabilities
The IndX acquisition will strengthen Accenture's Siemens Business Group and expand its ability to help manufacturers modernize product development, production, and supply chains through software, data, and AI-enabled technologies.
IndX specializes in Siemens software, including digital thread solutions, product lifecycle management, simulation, digital twins, SCADA, industrial edge computing, and cloud computing.
It has more than 650 professionals across Italy, the U.S., India, Germany, other European countries, and Mexico.
Alfahealth Deal Boosts Italy Healthcare Practice
The Alfahealth acquisition will expand Accenture's healthcare practice in Italy with a digital health platform focused on clinical processes, connected care data, patient access, and operational workflows.
About 1,200 Alfahealth professionals will join Accenture Italy's Health practice.
Accenture plans to establish two Centers of Excellence for Siemens DI solutions in Italy and India following the IndX deal’s close.
Terms of both transactions were not disclosed, and completion remains subject to customary closing conditions.
Accenture Earnings Preview And Analyst Price Targets
Accenture PLC is set to report earnings on June 18, 2026 (confirmed).
- EPS Estimate: $3.71 (Up from $3.49)
- Revenue Estimate: $18.76 Billion (Up from $17.70 Billion)
- Valuation: P/E of 13.6x (Indicates value opportunity)
Analyst Consensus & Recent Actions: The stock carries a Buy rating with an average price target of $247.13. Recent analyst moves include:
- Morgan Stanley: Downgraded to Equal-Weight (Lowers Target to $177.00) (June 15)
- JP Morgan: Overweight (Lowers Target to $201.00) (June 8)
- TD Cowen: Buy (Lowers Target to $258.00) (June 8)
How Accenture Ranks On Value, Growth, Quality And Momentum
Below is the Benzinga Edge scorecard for Accenture PLC, highlighting its strengths and weaknesses compared to the broader market:
- Value: Weak (Score: 25.27) — Trading at a steep premium relative to peers.
- Growth: Weak (Score: 21.07) — Limited growth prospects in the current market environment.
- Quality: Neutral (Score: 67.4) — Balance sheet remains healthy.
- Momentum: Bearish (Score: 3.8) — Stock is showing very weak performance indicators.
The Verdict: Accenture’s Benzinga Edge signal reveals a weak profile, particularly in value and growth, indicating challenges in the current market landscape.
The company maintains a neutral quality score, suggesting stability, but momentum remains a concern.
ACN Stock Price Activity: Accenture shares were down 0.02% at $165.49 during premarket trading on Wednesday, according to Benzinga Pro data.
Photo by Tobias Arhelger via Shutterstock
Login to comment